major depressive disorder

Relmada dumps depression asset after slew of phase 3 failures

The biotech has terminated the license agreement for esmethadone, months after canceling two phase 3 trials that were not expected to hit their goals.

Darren Incorvaia Jul 11, 2025 12:12pm

Alto's phase 2 depression trial misses primary efficacy endpoint

Jun 26, 2025 9:28am

Gilgamesh links psychedelic to 94% remission rate in depression

May 27, 2025 11:00am

Cartoon of businessmen standing around a broken target

J&J ends phase 3 depression program over 'insufficient efficacy'

Mar 7, 2025 4:55am

A puzzle of the brain with one missing piece

Takeda regains home rights to depression drug from Neurocrine

Jan 28, 2025 4:16am

Baseball sitting in a glove against a dark background

After 3rd phase 3 strike, Relmada's depression drug is out

Dec 9, 2024 2:30pm